Cholangiolocellular carcinoma

Summary

Cholangiolocellular carcinoma (MONDO:0004315) is a cancer. Molecularly, FGFR2::v Fusion OR FGFR2::? Fusion confers sensitivity to Pemigatinib in Cholangiolocellular Carcinoma (CIViC Level A). A subtype of intrahepatic cholangiocarcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Precision-medicine evidence (CIViC): 1 subtype–drug association

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	cholangiolocellular carcinoma
Mondo ID	MONDO:0004315
DOID	DOID:7642
NCIT	C41617
UMLS	C1516490
MedGen	273143
GARD	0023929
Anatomy (UBERON)	UBERON:0001282
Is cancer (heuristic)	yes

Also known as: cholangiocarcinoma of intralobular bile duct · cholangiolocellular carcinoma · CLC · intralobular bile duct cholangiocarcinoma

Disease family

This is a subtype of intrahepatic cholangiocarcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › digestive system cancer › liver cancer › biliary tract cancer › bile duct cancer › intrahepatic bile duct cancer › intrahepatic cholangiocarcinoma › cholangiolocellular carcinoma

Related subtypes (5): hilar cholangiocarcinoma, mucinous intrahepatic cholangiocarcinoma, signet ring cell intrahepatic cholangiocarcinoma, sarcomatous intrahepatic cholangiocarcinoma, perihilar intrahepatic cholangiocarcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.

Precision-medicine subtype map (CIViC)

Drug × molecular subtype: 1 predictive associations from 1 curated evidence items.

Molecular subtype	Therapy	Effect	Level	CIViC
FGFR2::v Fusion OR FGFR2::? Fusion	Pemigatinib	Sensitivity/Response	CIViC A	EID8173